The questions do not stop at weight
Longer follow-up and sleep apnea · 2023–2025
What happens when treatment stops?
Subject One poses beside a finish line. Then he notices the track continues around the corner. “You put it in the wrong place.” Doctide points to the follow-up calendar. “You assumed there was only one lap.” Subject One slowly takes off the victory wreath.
What changes here
In a withdrawal trial, participants switched to placebo regained weight on average. An on-treatment result was not a permanent finish line. [4]
Read the study details & dates
A serious event record
SURMOUNT-2, in people with obesity or overweight and type 2 diabetes, reported two deaths in one tirzepatide group. Investigators did not consider them treatment-related. An event occurring during a trial and an event caused by treatment are different claims. [1]
What happened after withdrawal?
SURMOUNT-4 first treated participants for 36 weeks, then randomized them to continue tirzepatide or switch to placebo for 52 weeks. Weight rose by 14.0% from the randomization point in the withdrawal group, while the continued-treatment group lost a further 5.5% on average. These are changes from week 36, not from the original starting weight. [4]
A longer diabetes-risk question
The SURMOUNT-1 extension followed participants with obesity and prediabetes for 176 weeks. Diabetes diagnoses were less frequent with tirzepatide. That trial finding is not a blanket diabetes-prevention indication. [2]
A sleep-apnea indication
FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. Two trials enrolled 469 adults without type 2 diabetes; the agency said the improvement likely related to weight reduction. [3]
What this does not establish
The scene is light; the event record is not rewritten for a joke. Subject One is not portrayed as dying and returning or as personally experiencing these outcomes.
Original sources
- SURMOUNT-2 primary publication
- Tirzepatide for obesity treatment and diabetes prevention
- FDA sleep-apnea approval
- SURMOUNT-4 randomized withdrawal study
Sources reviewed 2026-10-11. Study and publication dates are stated separately where known.
Subject One is fictional. Separate studies, species and populations are not a single patient’s experience. How to read the story